Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis : data from the Accelerating Medicines Partnership Lupus Network
© 2024. The Author(s)..
BACKGROUND: Leveraging the Accelerating Medicines Partnership (AMP) Lupus Nephritis (LN) dataset, we evaluated longitudinal patterns, rates, and predictors of response to standard-of-care therapy in patients with lupus nephritis.
METHODS: Patients from US academic medical centers with class III, IV, and/or V LN and a baseline urine protein/creatinine (UPCR) ratio ≥ 1.0 (n = 180) were eligible for this analysis. Complete response (CR) required the following: (1) UPCR < 0.5; (2) normal serum creatinine (≤ 1.3 mg/dL) or, if abnormal, ≤ 125% of baseline; and (3) prednisone ≤ 10 mg/day. Partial response (PR) required the following: (1) > 50% reduction in UPCR; (2) normal serum creatinine or, if abnormal, ≤ 125% of baseline; and (3) prednisone dose ≤ 15 mg/day.
RESULTS: Response rates to the standard of care at week 52 were CR = 22.2%; PR = 21.7%; non-responder (NR) = 41.7%, and not determined (ND) = 14.4%. Only 8/180 (4.4%) patients had a week 12 CR sustained through week 52. Eighteen (10%) patients attained a week 12 PR or CR and sustained their responses through week 52 and 47 (26.1%) patients achieved sustained PR or CR at weeks 26 and 52. Week 52 CR or PR attainment was associated with baseline UPCR > 3 (ORadj = 3.71 [95%CI = 1.34-10.24]; p = 0.012), > 25% decrease in UPCR from baseline to week 12 (ORadj = 2.61 [95%CI = 1.07-6.41]; p = 0.036), lower chronicity index (ORadj = 1.33 per unit decrease [95%CI = 1.10-1.62]; p = 0.003), and positive anti-dsDNA antibody (ORadj = 2.61 [95%CI = 0.93-7.33]; p = 0.069).
CONCLUSIONS: CR and PR rates at week 52 were consistent with the standard-of-care response rates observed in prospective registrational LN trials. Low sustained response rates underscore the need for more efficacious therapies and highlight how critically important it is to understand the molecular pathways associated with response and non-response.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Arthritis research & therapy - 26(2024), 1 vom: 20. Feb., Seite 54 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Izmirly, Peter M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.02.2024 Date Revised 09.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13075-024-03275-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36868685X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36868685X | ||
| 003 | DE-627 | ||
| 005 | 20240409232456.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13075-024-03275-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM36868685X | ||
| 035 | |a (NLM)38378664 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Izmirly, Peter M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis |b data from the Accelerating Medicines Partnership Lupus Network |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Leveraging the Accelerating Medicines Partnership (AMP) Lupus Nephritis (LN) dataset, we evaluated longitudinal patterns, rates, and predictors of response to standard-of-care therapy in patients with lupus nephritis | ||
| 520 | |a METHODS: Patients from US academic medical centers with class III, IV, and/or V LN and a baseline urine protein/creatinine (UPCR) ratio ≥ 1.0 (n = 180) were eligible for this analysis. Complete response (CR) required the following: (1) UPCR < 0.5; (2) normal serum creatinine (≤ 1.3 mg/dL) or, if abnormal, ≤ 125% of baseline; and (3) prednisone ≤ 10 mg/day. Partial response (PR) required the following: (1) > 50% reduction in UPCR; (2) normal serum creatinine or, if abnormal, ≤ 125% of baseline; and (3) prednisone dose ≤ 15 mg/day | ||
| 520 | |a RESULTS: Response rates to the standard of care at week 52 were CR = 22.2%; PR = 21.7%; non-responder (NR) = 41.7%, and not determined (ND) = 14.4%. Only 8/180 (4.4%) patients had a week 12 CR sustained through week 52. Eighteen (10%) patients attained a week 12 PR or CR and sustained their responses through week 52 and 47 (26.1%) patients achieved sustained PR or CR at weeks 26 and 52. Week 52 CR or PR attainment was associated with baseline UPCR > 3 (ORadj = 3.71 [95%CI = 1.34-10.24]; p = 0.012), > 25% decrease in UPCR from baseline to week 12 (ORadj = 2.61 [95%CI = 1.07-6.41]; p = 0.036), lower chronicity index (ORadj = 1.33 per unit decrease [95%CI = 1.10-1.62]; p = 0.003), and positive anti-dsDNA antibody (ORadj = 2.61 [95%CI = 0.93-7.33]; p = 0.069) | ||
| 520 | |a CONCLUSIONS: CR and PR rates at week 52 were consistent with the standard-of-care response rates observed in prospective registrational LN trials. Low sustained response rates underscore the need for more efficacious therapies and highlight how critically important it is to understand the molecular pathways associated with response and non-response | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Lupus nephritis | |
| 650 | 4 | |a Outcome | |
| 650 | 4 | |a Renal biopsy | |
| 650 | 4 | |a Systemic lupus erythematosus (SLE) | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Creatinine |2 NLM | |
| 650 | 7 | |a AYI8EX34EU |2 NLM | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 700 | 1 | |a Kim, Mimi Y |e verfasserin |4 aut | |
| 700 | 1 | |a Carlucci, Philip M |e verfasserin |4 aut | |
| 700 | 1 | |a Preisinger, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Brooke Z |e verfasserin |4 aut | |
| 700 | 1 | |a Deonaraine, Kristina |e verfasserin |4 aut | |
| 700 | 1 | |a Zaminski, Devyn |e verfasserin |4 aut | |
| 700 | 1 | |a Dall'Era, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Kalunian, Kenneth |e verfasserin |4 aut | |
| 700 | 1 | |a Fava, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Belmont, H Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Putterman, Chaim |e verfasserin |4 aut | |
| 700 | 1 | |a Anolik, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Barnas, Jennifer L |e verfasserin |4 aut | |
| 700 | 1 | |a Diamond, Betty |e verfasserin |4 aut | |
| 700 | 1 | |a Davidson, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Wofsy, David |e verfasserin |4 aut | |
| 700 | 1 | |a Kamen, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a James, Judith A |e verfasserin |4 aut | |
| 700 | 1 | |a Guthridge, Joel M |e verfasserin |4 aut | |
| 700 | 1 | |a Apruzzese, William |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Deepak A |e verfasserin |4 aut | |
| 700 | 1 | |a Weisman, Michael H |e verfasserin |4 aut | |
| 700 | 0 | |a Accelerating Medicines Partnership in RA/SLE Network |e verfasserin |4 aut | |
| 700 | 1 | |a Petri, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Buyon, Jill |e verfasserin |4 aut | |
| 700 | 1 | |a Furie, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Tabechian, Darren |e investigator |4 oth | |
| 700 | 1 | |a Thiele, Ralf |e investigator |4 oth | |
| 700 | 1 | |a Hossler, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Boyce, Brendan |e investigator |4 oth | |
| 700 | 1 | |a Meednu, Nida |e investigator |4 oth | |
| 700 | 1 | |a Rangel-Moreno, Javier |e investigator |4 oth | |
| 700 | 1 | |a Ritchlin, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Bykerk, Vivian |e investigator |4 oth | |
| 700 | 1 | |a Donlin, Laura |e investigator |4 oth | |
| 700 | 1 | |a Goodman, Susan |e investigator |4 oth | |
| 700 | 1 | |a Ivashkiv, Lionel |e investigator |4 oth | |
| 700 | 1 | |a Pernis, Alessandra |e investigator |4 oth | |
| 700 | 1 | |a DiCarlo, Ed |e investigator |4 oth | |
| 700 | 1 | |a Orange, Dana |e investigator |4 oth | |
| 700 | 1 | |a Carrino, John |e investigator |4 oth | |
| 700 | 1 | |a Nwawka, Oganna |e investigator |4 oth | |
| 700 | 1 | |a Yoshimi, Endo |e investigator |4 oth | |
| 700 | 1 | |a Satija, Rahul |e investigator |4 oth | |
| 700 | 1 | |a Ivashkiv, Lionel |e investigator |4 oth | |
| 700 | 1 | |a Darnell, Robert |e investigator |4 oth | |
| 700 | 1 | |a Figgie, Mark |e investigator |4 oth | |
| 700 | 1 | |a McNamara, Michael |e investigator |4 oth | |
| 700 | 1 | |a Moreland, Larry W |e investigator |4 oth | |
| 700 | 1 | |a McGeachy, Mandy J |e investigator |4 oth | |
| 700 | 1 | |a Kolls, Jay |e investigator |4 oth | |
| 700 | 1 | |a Wise, Aaron |e investigator |4 oth | |
| 700 | 1 | |a Cordle, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Gregersen, Peter |e investigator |4 oth | |
| 700 | 1 | |a Horowitz, Diane |e investigator |4 oth | |
| 700 | 1 | |a Filer, Andrew D |e investigator |4 oth | |
| 700 | 1 | |a Turner, Jason |e investigator |4 oth | |
| 700 | 1 | |a Adams, Holly |e investigator |4 oth | |
| 700 | 1 | |a Pitzalis, Costantino |e investigator |4 oth | |
| 700 | 1 | |a Kelly, Stephen |e investigator |4 oth | |
| 700 | 1 | |a Hands, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Brenner, Michael |e investigator |4 oth | |
| 700 | 1 | |a Todd, Derrick |e investigator |4 oth | |
| 700 | 1 | |a Wei, Kevin |e investigator |4 oth | |
| 700 | 1 | |a Rao, Deepak |e investigator |4 oth | |
| 700 | 1 | |a Mizoguchi, Fumitaka |e investigator |4 oth | |
| 700 | 1 | |a Holers, V Michael |e investigator |4 oth | |
| 700 | 1 | |a Deane, Kevin D |e investigator |4 oth | |
| 700 | 1 | |a Seifert, Jennifer A |e investigator |4 oth | |
| 700 | 1 | |a Banda, Nirmal K |e investigator |4 oth | |
| 700 | 1 | |a Firestein, Gary S |e investigator |4 oth | |
| 700 | 1 | |a Boyle, David |e investigator |4 oth | |
| 700 | 1 | |a Ben-Artzi, Ami |e investigator |4 oth | |
| 700 | 1 | |a Forbess, Lindsy |e investigator |4 oth | |
| 700 | 1 | |a Gravallese, Ellen |e investigator |4 oth | |
| 700 | 1 | |a Salomon-Escoto, Karen |e investigator |4 oth | |
| 700 | 1 | |a Perlman, Harris |e investigator |4 oth | |
| 700 | 1 | |a Mandelin, Arthur |e investigator |4 oth | |
| 700 | 1 | |a Bacalao, Emily |e investigator |4 oth | |
| 700 | 1 | |a Parks, Deborah |e investigator |4 oth | |
| 700 | 1 | |a Atkinson, John |e investigator |4 oth | |
| 700 | 1 | |a Bathon, Joan |e investigator |4 oth | |
| 700 | 1 | |a Matteson, Eric |e investigator |4 oth | |
| 700 | 1 | |a Bridges, Louis |e investigator |4 oth | |
| 700 | 1 | |a Hughes, Laura B |e investigator |4 oth | |
| 700 | 1 | |a Fox, David |e investigator |4 oth | |
| 700 | 1 | |a Ike, Robert |e investigator |4 oth | |
| 700 | 1 | |a Lee, Chun-Hao |e investigator |4 oth | |
| 700 | 1 | |a Fine, Derek |e investigator |4 oth | |
| 700 | 1 | |a Monroy-Trujillo, Manny |e investigator |4 oth | |
| 700 | 1 | |a Anolik, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Shah, Ummara |e investigator |4 oth | |
| 700 | 1 | |a Weisman, Michael |e investigator |4 oth | |
| 700 | 1 | |a Ishimori, Mariko |e investigator |4 oth | |
| 700 | 1 | |a Buyon, Jill P |e investigator |4 oth | |
| 700 | 1 | |a Clancy, Robert M |e investigator |4 oth | |
| 700 | 1 | |a Izmirly, Peter |e investigator |4 oth | |
| 700 | 1 | |a Belmont, Michael |e investigator |4 oth | |
| 700 | 1 | |a Bornkamp, Nicole |e investigator |4 oth | |
| 700 | 1 | |a Der, Evan |e investigator |4 oth | |
| 700 | 1 | |a Goilav, Beatrice |e investigator |4 oth | |
| 700 | 1 | |a Jordan, Nicole |e investigator |4 oth | |
| 700 | 1 | |a Schwartz, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Pullman, James |e investigator |4 oth | |
| 700 | 1 | |a Smilek, Dawn |e investigator |4 oth | |
| 700 | 1 | |a Tosta, Patti |e investigator |4 oth | |
| 700 | 1 | |a Kretzler, Matthias |e investigator |4 oth | |
| 700 | 1 | |a Berthier, Celine C |e investigator |4 oth | |
| 700 | 1 | |a Woodle, F Steve |e investigator |4 oth | |
| 700 | 1 | |a Hildeman, Dave |e investigator |4 oth | |
| 700 | 1 | |a Brenner, Michael |e investigator |4 oth | |
| 700 | 1 | |a Rao, Deepak |e investigator |4 oth | |
| 700 | 1 | |a Robinson, William |e investigator |4 oth | |
| 700 | 1 | |a Nolan, Garry |e investigator |4 oth | |
| 700 | 1 | |a Gonzales, Veronica |e investigator |4 oth | |
| 700 | 1 | |a Brenner, Michael |e investigator |4 oth | |
| 700 | 1 | |a Rao, Deepak |e investigator |4 oth | |
| 700 | 1 | |a Wei, Kevin |e investigator |4 oth | |
| 700 | 1 | |a Lederer, Jim |e investigator |4 oth | |
| 700 | 1 | |a Keegan, Joshua |e investigator |4 oth | |
| 700 | 1 | |a Chicoine, Adam |e investigator |4 oth | |
| 700 | 1 | |a Liu, Yanyan |e investigator |4 oth | |
| 700 | 1 | |a Watts, Gerald |e investigator |4 oth | |
| 700 | 1 | |a Hacohen, Nir |e investigator |4 oth | |
| 700 | 1 | |a Arazi, Arnon |e investigator |4 oth | |
| 700 | 1 | |a Lieb, David |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Arthritis research & therapy |d 2003 |g 26(2024), 1 vom: 20. Feb., Seite 54 |w (DE-627)NLM124870457 |x 1478-6362 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2024 |g number:1 |g day:20 |g month:02 |g pages:54 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13075-024-03275-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2024 |e 1 |b 20 |c 02 |h 54 | ||